Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S3273: sourced facts only. name: "A polycyclic aromatic naphthodianthrone compound, S3273, was the most potent CD39 enhancer with EC50 value of 5.66 μM." [PMID:41506549]; target: "A polycyclic aromatic naphthodianthrone compound, S3273, was the most potent CD39 enhancer with EC50 value of 5.66 μM." [PMID:41506549]; developer: "Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, China; Key Laboratory of Acupuncture for Senile Disease (Chengdu University of TCM), Ministry of Education, Chengdu 611130, China; Acupunctcure Point Effects Key Laboratory of Sichuan Province, Chengdu 611130, China. Electronic address: [email protected]." [PMID:41506549]; stage: "S3273 calms cytokine storm to reverse lung damage in LPS-challenged mice, and these effects are at least partly through the modulation on CD39-P2X7R-IL-17A route." [PMID:41506549]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S3273.